USSTOCK.TODAY
Regular Market
Log in Sign up

Johnson & Johnson vs. Pfizer: A Comparison of 2026 Healthcare Investments

The Motley Fool +1 ·

JNJ Johnson & Johnson
$263.73 +0.88%
View chart & analysis →
  1. 1Johnson & Johnson's total revenue for fiscal year 2025 was approximately $94.2 billion.
  2. 2Pfizer expects revenue to decrease significantly from 2026 to 2030 due to the expiration of patents and regulatory exclusivity.
  3. 3Johnson & Johnson announced plans to spin off its orthopedic business in October 2025.

So what's the key point?

Johnson & Johnson recorded $94.2 billion in revenue and plans to separate its orthopedic business. Pfizer is expected to see a decline in revenue as its patents expire.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Johnson & Johnson beats Q3 estimates and raises annual guidance Nasdaq +1 · 1h agoJohnson & Johnson reports third-quarter results beating expectations Reuters +1 · 3h agoUS semiconductor stocks mixed in premarket amid memory competition and revenue outlook concerns Stocktwits +3 · 10h ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news